Fgfr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fgfr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fgfr Today - Breaking & Trending Today

Patient Perspective Regarding FGFRi Adverse Event Profiles

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events. ....

Chaundra Bishop , Caroline Kuhlman , Lipika Goyal , R Katie Kelley , Onclive Insights , Bile Duct Cancer , Intrahepatic Cholangiocarcinoma , Extrahepatic Cholangiocarcinoma , Fgfr Inhibitors , Fgfri Adverse Events , Adverse Events , Fgfr Inhibitors Adverse Effects , Fgfr Inhibitors Side Effects , Biliary Tract Cancer ,

Key Highlights For Patient Education Surrounding FGFR Inhibitors

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors. ....

Caroline Kuhlman , Chaundra Bishop , R Katie Kelley , Lipika Goyal , Taiho Oncology Inc , Taiho Oncology , Onclive Insights , Gastrointestinal Cancer , Gi Cancer , Patient Education , Fgfr Inhibitors , Key Highlights , Cholangiocarcinoma Treatment , Gi Cancer Treatment ,

Common Adverse Events Associated With FGFRi Therapy

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more. ....

Chaundra Bishop , Caroline Kuhlman , Lipika Goyal , R Katie Kelley , Taiho Oncology Inc , Taiho Oncology , Onclive Insights , Gi Cancer , Gastrointestinal Cancer , Fgfr Inhibitors , Adverse Events , Adverse Effects , Fgfri Therapy , Cholangiocarcinoma Treatment , Gi Cancer Treatment , Gastrointestinal Cancer Treatment ,

Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma

1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with an HR of 0.64. 2. Grade 3 or 4 treatment-related adverse events occurred in 45.9% in the erdafitinib group and 46.4% in the chemotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Cisplatin-based chemotherapy and ....

Rating Level , Median Dor , Urothelial Carcinoma , Chronic Disease ,

Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023

An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations. ....

Sia Daneshmand , Cohort 1 , Intravesical Chemotherapy , Bcg Therapy , Mitomycin C , Gemcitabine Monotherapy , Tar 210 Study ,